---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-028564"
form_type: "8-K/A"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2026-07-15T21:09:08+00:00"
generated_at: "2026-07-15T21:10:05.303428+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics files Cullgen financials for merger; Cullgen FY2025 net loss $10.8M

## Summary
- Cullgen FY2025 net loss $10.8M, accumulated deficit $132.2M as of Dec 31, 2025.
- Cullgen revenue $15.4M from collaboration; R&D expense $19.3M, G&A $10.2M.
- Cullgen had $40.2M in cash and short-term investments; total assets $53.6M.
- Redeemable convertible preferred stock $173.5M; stockholders' deficit $127.4M.
- Merger closed May 4, 2026; this amendment provides required financial statements.

## SEC filing metadata
- accession: 0001140361-26-028564
- form_type: 8-K/A
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2026-07-15T21:09:08+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036126028564/0001140361-26-028564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036126028564/ef20077460_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-028564
- JSON: https://secwatch.observer/filing/0001140361-26-028564.json
- Plain text: https://secwatch.observer/filing/0001140361-26-028564.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.